Wednesday, July 8, 2026

pharma · Hereditary Angioedema · Influenza · BCRX

Biocryst

Biocryst is a pharma organization headquartered in München, DE. It trades on NYSE under ticker BCRX. Primary therapeutic focus areas include Hereditary Angioedema, Influenza, Paroxysmal Nocturnal Hemoglobinuria, Paroxysm

München, DE HQ
1986 Founded
6 Employees
Public company Type
BCRX · NYSE Ticker
Company details
Clinical program

Peramivir 200 mg

Phase 2 · small molecule · Influenza

Peramivir 200 mg for Influenza is a Phase 2 program (small_molecule) at Biocryst with 1 ClinicalTrials.gov record(s).

← All Biocryst projects Phase 2 small molecule completed

Internal code BCX1812-201

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Biocryst
Phase
Phase 2
Modality
small_molecule
Indication
Influenza
Status
completed
Trials
1